Mickael Henry-Szatkowski

Mickael Henry-Szatkowski

Auto-generated profile, based on publicly available information

Mickael Henry-Szatkowski

IQVIA, Paris, France

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2026 in Expert Review of Vaccines
Verified
Journal Article
Open access
OHOscar Herrera-Restrepo
Oscar Herrera-Restrepo
LBLaurie Batchelder
Laurie Batchelder
TPThatiana Pinto
Thatiana Pinto
MHMickael Henry-Szatkowski
Mickael Henry-Szatkowski
DZDian Zhang
Dian Zhang
JSJana Shaw
Jana Shaw
Invasive meningococcal disease (IMD) is a vaccine-preventable, serious disease. In 2023-2024, the United States (US) Advisory Committee on Immunization Practices (ACIP) proposed revisions to the adolescent meningococcal vaccine schedule. This survey aimed to understand healthcare professionals' (HCPs') perspectives on these revisions and the potential role of the meningococcal serogroups A, B, C, W, Y (MenABCWY) vaccine. An online survey was conducted in May - June 2025 among US HCPs who regularly recommend meningococcal vaccines for 16-23-year-old patients. Responses were analyzed descriptively. Of 302 HCPs, 73.2% felt the MenABCWY vaccine provides significant value to the meningococcal vaccination program, and almost half preferred a two-dose MenABCWY schedule over the ACIP recommendation, wherein a MenABCWY dose is followed by a MenB dose. Most HCPs indicated concern with removing MenACWY vaccination for 11-12-year-olds (84.8%). Comparatively, fewer were concerned about changing the MenB vaccine recommendation from shared clinical decision-making to risk-based (60.6%) and administering the second MenB dose closer to college entry (48.7%). While HCPs were receptive to revisions that simplify the vaccine schedule, this was not without concerns. The adolescent vaccination platform is essential to ensure continued protection against IMD; any changes will require clear, evidence-based guidance.

4 March 2026 in Current Medical Research and Opinion
Verified
Journal Article
Open access
ZRZoe Raglow
Zoe Raglow
DKDan Kaul
Dan Kaul
ARAna María Rodriguez
Ana María Rodriguez
AGAna Sofia Oliveira Gonçalves
Ana Sofia Oliveira Gonçalves
MHMickael Henry-Szatkowski
Mickael Henry-Szatkowski
BSBob G. Schultz
Bob G. Schultz
Post-transplant cytomegalovirus (CMV) infection is one of the most common viral infections experienced by transplant recipients1,2. Despite prevention strategies, CMV infection continues to occur w...